Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. orm 1449/PTO

TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use	<b>a</b> s	many	sneets	as	necessary	

of

Sheet

Complete if Known				
Application Number	10/005,876			
Filing Date	December 7, 2001			
First Named Inventor	Jonathan D. CHESNUT			
Art Unit	1636			
Examiner Name	Ketter, James S.			
Attorney Docket Number	0942.5340002/BJD/JKM			

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2 (If Known)</sup>			or Relevant Figures Appear
JK	AJ13	2003/0022179 A1	01/30/2003	Chesnut et al.	
1	AK13	6,916,632 B2	07/12/2005	Chesnut et al.	
	AA14	2004/0132133 A1	07/08/2004	Bennett	
	AB14	6,548,277 B1	04/15/2003	Shuman	
			ļ		
			<u> </u>		
	-	<u> </u>			
					ļ
					<del> </del>
				ļ	
	1				

		Fo	REIGN PATENT DO	DCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	MM-DD-YYYY Applicant of Cited Document Relevant Pas		Pages, Columns, Lines, Where	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)			Relevant Passages or Relevant Figures Appear	Té
JK	AO14	WO 96/23904 A1	08/08/1996	Replicon, Inc.		
JK	AP14	WO 98/56943 A1	12/17/1998	Sloan-Kettering Institute for Cancer Research and Invitrogen Corporation		
						$\vdash$
		<del> </del>				一

509736 1.DOC

Examiner		Date	05/08/2006
Signature	/James Ketter/	Considered	05/08/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information and the second to persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (07-05)

Under the Paperwork Complete if Known Substitute for form 1449/PTO Application Number 10/005,876 TENTH SUPPLEMENTAL December 7, 2001 Filing Date INFORMATION DISCLOSURE Jonathan D. CHESNUT First Named Inventor STATEMENT BY APPLICANT 1636 Art Unit (Use as many sheets as necessary) Ketter, James S. Examiner Name 0942.5340002/BJD/JKM **Attorney Docket Number** of 2 Sheet

		NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²
<b>ј</b> к	AT137	Bliska, J.B. and Cozzarelli, N.R., "Use of Site-specific Recombination as a Probe of DNA Structure and Metabolism in Vivo," J. Mol. Biol. 194:205-218, Academic Press Inc. (1987)	
AR138		Chatterjee, P.K. and Sternberg, N.L., "Retrofitting high molecular weight DNA cloned in P1: introduction of reporter genes, markers selectable in mammalian cells and generation of nested deletions," <i>Genet. Anal. Biomol. Engin.</i> 13:33-42, Elsevier Science B.V. (1996)	
;	AS138	Cheng, C. and Shuman, S., "Recombinogenic Flap Ligation Pathway for Intrinsic Repair of Topoisomerase IB-Induced Double-Strand Breaks," Mol. Cell. Biol. 20:8059-8068, American Society for Microbiology (November 2000)	Í
	AT138	Cheng, C., et al., "Conservation of Structure and Mechanism between Eukaryotic Topoisomerase I and Site-Specific Recombinases," Cell 92:841-850, Cell Press (1998)	
AR139		Kanegae, Y., et al., "Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase," Nucleic Acids Res. 23:3816-3821, Oxford University Press (1995)	
	AS139	Kim, R.A. and Wang, J.C., "Identification of the Yeast TOP3 Gene Product as a Single Strand-specific DNA Topoisomerase," J. Biol. Chem. 267:17178-17185, The American Society for Biochemistry and Molecular Biology, Inc. (1992)	
	AT139	Liber, A., et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre- Mediated Excision Exhibit Different Biological Properties Compared with First- Generation Vectors In Vitro and In Vivo," J. Virol. 70:8944-8960, American Society for Microbiology (1996)	
	AR140	Sekiguchi, J. and Shuman, S., "Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA," <i>Nucleic Acids Res.</i> 22:5360-5365, Oxford University Press (1994)	
	AS140	Shuman, S., "Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme," Biochim. Biophys. Acta 1400:321-337, Elsevier Science B.V. (1998)	
	AT140	Walhout, A.J.M., et al., "Protein Interaction Mapping in C. elegans Using Proteins Involved in Vulval Development," Science 287:116-122, American Association for the Advancement of Science (January 2000)	

Examiner		Date	
Signature	/James Ketter/	Considered	05/08/2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it contains a valid OMB control number.

Substitute for	Substitute for form 1449/PTO			Ca	Complete if Known		
·				Application Number	10/005,876		
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE				Filing Date	December 7, 2001		
				First Named Inventor	Jonathan D. CHESNUT		
STATE	STATEMENT BY APPLICANT			Art Unit	1636		
(Use as many sheets as necessary)		Examiner Name	Ketter, James S.				
Sheet	12	of	2	Attorney Docket Number	0942.5340002/BJD/JKM		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>				
JK	AR141	Walhout, A.J.M., et al., "GATEWAY Recombination Cloning: Application to the Cloning of Large Numbers of Open Reading Frames or ORFeomes," Meth. Enzymol. 328:575-592, Academic Press (January 2000)					
JK	AS141	Wang, Y., et al., "Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene," Proc. Natl. Acad. Sci USA 93:3932-3936, The National Academy of Sciences (1996)					
	·						
	-	, .					
		·					

509737\_1.DOC

Examiner		Date	
Signature	/James Retter/	Considered	05/08/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through clauter in not in continuation to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	10	16	6361972	2002-03-26	Harrington et al.	
1		17	6365377	2002-04-02	. Patten et al.	B1
		18	6410266	2002-06-25	Harrington et al.	] .
	$\prod$	19	6410317	2002-06-25	Farmer, A.F.	B1
Ē		20	6436707	2002-08-20	Zambrowicz et al.	]

## **US Published Applications**

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind Class Subclass
	1	20030027337	2003-02-06	Droge et al.	
	2	20020007051	2002-01-17	Cheo et al.	A1
	3	20020068290	2002-06-06	Yarovinsky .	A1

## Signature

Examiner Name	Date
1. NETTER	1/8/04